Aicuris...Presents New Phase 3 Data at ESCMID 2026 (The Manila Times) - Apr 16, 2026 - "Tended treatment up to 42 days; among patients who continued therapy, 82.4% of those treated with pritelivir achieved complete lesion healing compared with 42.0% with investigator's choice therapy (ICT), resulting in an adjusted treatment difference of 40.2%; Pritelivir treatment significantly reduced viral replication and viral burden, shortening the median time to undetectable HSV in lesions to 9 days compared with 21 days with ICT (p = 0.0581)"
P3 data • Herpes Simplex
|